Table 1.
Characteristics of the randomized controlled trials included in the present meta-analysis.
| References | Study design | Number and type of concomitant AEDs | Gender (male/female) | Age, years (mean ± SD) | Duration of epilepsy (Year/Month ± SD) | Duration of treatment | LCM dosage (mg/day) or Placebo | Seizure classification, n (%) patients | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Simple partial seizure | Complex partial seizure | Secondary partial attack | ||||||||
| Ben-Menachem et al. (17) | 8w-baseline 6w-titration period 12w-maintenance period |
1-2/ CBZ, LTG, LEV, OXC, et al. |
47/50 46/61 53/55 45/61 |
38.9 ± 11.11 39.9 ± 11.71 41.2 ± 11.61 39.4 ± 10.53 |
24.6 ± 11.77 25.1 ± 12.89 24.7 ± 13.08 23.6 ± 12.74 |
26w | Placebo 200mg 400 mg 600 mg |
33(34) 48(45) 41(38) 50(47) |
83(86) 101(94) 94(87) 96(91) |
73(75) 79(74) 77(71) 70(66) |
| Halasz et al. (19) | 8w-baseline 4w-titration period 12w-maintenance period 2w-transition period |
1-3/ CBZ, LEV, VPA,; TPM, et al. |
91/72 90/73 69/90 |
38.5 ± 10.93 36.9 ± 11.70 37.9 ± 12.96 |
21.1 ± 12.23 22.9 ± 12.30 22.8 ± 13.15 |
26w | Placebo 200 mg 400 mg |
61(37.4) 67(41.1) 58(36.5) |
138(84.7) 142(87.1) 146(91.8) |
130(79.8) 125(76.7) 127(79.9) |
| Chung et al. (20) | 8w-baseline 6w-titration period 12w-maintenance period 2w- transition period |
1-3/LEV, CBZ, LGT, et al. | 49/55 104/100 47/50 |
38.1 ± 11.96 39.1 ± 12.37 36.8 ± 11.76 |
25.4 ± 13.34 24.5 ± 13.16 23.4 ± 13.28 |
28w | Placebo 400 mg 600 mg |
41(39.4) 73(36.3) 35(36.1) |
86(82.7) 170(84.6) 75(77.3) |
45(43.3) 84(41.8) 47(48.5) |
| Hong et al. (18) | 8w-baseline 4w-titration period 12w-maintenance period 2w- transition period or 3w-taper period |
1-3/CBZ, VPA, OXC, et al. |
102/82 94/89 104/76 |
31.8 ± 12.0 33.2 ± 12.2 32.3 ± 11.9 |
16.8 ± 11.5 18.3 ± 10.9 17.9 ± 11.7 |
27w | Placebo 200 mg 400 mg |
60(32.8) 64(35.2) 61(34.1) |
183(99.5) 169(92.3) 173(96.1) |
129(70.5) 114(62.6) 107(59.8) |
| Chung et al. (21) | 4w-increasing period 12w-maintenance period 2w-reduction period |
1-4/ CBZ, LEV, OXC, TMP, et al. |
90/79 97/75 93/81 |
30.54 ± 12.04 29.61 ± 12.74 30.50 ± 11.18 |
158.7 ± 110.57m 159.6 ± 101.17m 172.9 ± 120.60m |
18w | Placebo 200 mg 400 mg |
33(19.53) 36(20.93) 38(21.84) |
105(62.13) 102(59.30) 104(59.77) |
72(42.60) 68(39.53) 76(43.68) |
AEDs, anti-epileptic drugs; CBZ, Carbamazepine; VPA, valproic acid; LEV, levetiracetam; LTG, Lamotrigine; OXC, Oxcarbazepine; TPM, Topiramate; SD, standard deviation.